Haemonetics Corporation
HAE
Hisse Senetlerindeki Sıralama
#3273
Haemonetics Corporation is a healthcare enterprise dedicated to providing... Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Hisse Fiyatı
$118.49
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$5.39B
Değişim (1 gün)
-2.43%
Değişim (1 yıl)
135.75%
Ülke
US
Ticaret Haemonetics Corporation (HAE)
Kategori
Healthcare
Haemonetics Corporation (HAE) için Faaliyet Marjı
October 2026 itibarıyla Faaliyet Marjı TTM: 18.18%
Haemonetics Corporation şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) 18.18%'dir. 2024 yılı sonunda şirketin faaliyet marjı 12.60% idi.
Haemonetics Corporation için 2000 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
| Yıl | Faaliyet Marjı | Değiştir |
|---|---|---|
| 2026 (TTM) | 18.18% | 11.53% |
| 2025 | 16.30% | 29.37% |
| 2024 | 12.60% | -5.62% |
| 2023 | 13.35% | 64.21% |
| 2022 | 8.13% | 22.07% |
| 2021 | 6.66% | -57.23% |
| 2020 | 15.57% | 80.42% |
| 2019 | 8.63% | 38.97% |
| 2018 | 6.21% | -383.56% |
| 2017 | -2.19% | -54.75% |
| 2016 | -4.84% | -208.76% |
| 2015 | 4.45% | -11.71% |
| 2014 | 5.04% | -20.38% |
| 2013 | 6.33% | -48.07% |
| 2012 | 12.19% | -25.40% |
| 2011 | 16.34% | 26.67% |
| 2010 | 12.90% | -9.85% |
| 2009 | 14.31% | 5.14% |
| 2008 | 13.61% | -2.51% |
| 2007 | 13.96% | -40.82% |
| 2006 | 23.59% | 50.93% |
| 2005 | 15.63% | 24.05% |
| 2004 | 12.60% | 13.31% |
| 2003 | 11.12% | -2.37% |
| 2002 | 11.39% | 149.23% |
| 2001 | 4.57% | -62.23% |
| 2000 | 12.10% | 0.00% |
Benzer şirketler veya rakipler için Faaliyet Marjı
| Şirket | Faaliyet Marjı | Faaliyet Marjı Farkı | Ülke |
|---|---|---|---|
| 17.03% | -99.06% |
US
|
|
| 17.86% | -99.02% |
IE
|
|
| 22.03% | -98.79% |
US
|
|
| 21.46% | -98.82% |
US
|
|
| 0.00% | - |
DE
|
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.